BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Update

BiomX Inc. (NYSEAMERICAN:PHGE) was the recipient of a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 594,279 shares, a growth of 200.9% from the May 14th total of 197,532 shares. Based on an average trading volume of 38,808,369 shares, the days-to-cover ratio is presently 0.0 days. Currently, 7.5% of the company’s shares are short sold.

Insider Transactions at BiomX

In other BiomX news, Director Reuven Yeganeh sold 530,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $5.00, for a total value of $2,650,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 21.80% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BiomX stock. Alyeska Investment Group L.P. acquired a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned approximately 5.99% of BiomX at the end of the most recent reporting period. Hedge funds and other institutional investors own 40.57% of the company’s stock.

BiomX Trading Up 10.6%

NYSEAMERICAN PHGE opened at $0.71 on Friday. The business’s 50-day moving average price is $1.37 and its two-hundred day moving average price is $3.19. BiomX has a 12 month low of $0.36 and a 12 month high of $14.71. The firm has a market capitalization of $7.90 million, a PE ratio of -0.22 and a beta of 1.18.

BiomX (NYSEAMERICAN:PHGE) last released its quarterly earnings results on Wednesday, May 20th. The company reported $7.38 EPS for the quarter. As a group, analysts forecast that BiomX will post -5.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright cut shares of BiomX from a “buy” rating to a “hold” rating in a research report on Monday, March 9th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $26.00.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.